UBS analyst Eliana Merle initiates coverage on $Gilead Sciences (GILD.US)$ with a hold rating, and sets the target price at $96.
According to TipRanks data, the analyst has a success rate of 34.8% and a total average return of -7.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Gilead Sciences (GILD.US)$'s main analysts recently are as follows:
The firm noted an increase in their HIV PrEP and Livdelzi estimates for Gilead, and anticipates meaningful growth in Gilead's HIV base business due to the expansion of the PrEP market with the introduction of lenacapravir. Despite a 30% increase in share value over the past six months, the growth of the PrEP market remains uncertain, leading to the current valuation of the shares being deemed appropriate.
Following the Q3 reports, updated models in the biotechnology group suggest growth for Gilead's base HIV business, with the potential launch of lenacapavir anticipated around late 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
